Company Overview of Danube Pharmaceuticals, Inc.
Danube Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the research and development of drugs and technologies for the treatment of ophthalmic and other related diseases. Its DNB-001 is a small molecule for the treatment of glaucoma. The company also engages in the research of efficacy of novel oral therapy with a dual mechanism of action, in lowering the intraocular pressure ("IOP") in patients with ocular hypertension. The company was incorporated in 2005 and is based in New York, New York.
689 Fifth Avenue
New York, NY 10022
Founded in 2005
Key Executives for Danube Pharmaceuticals, Inc.
Similar Private Companies By Industry
|Evogene, Inc.||United States|
|Alidex, Inc.||United States|
|Epeius Biotechnologies Corporation||United States|
|MetaMorphix Inc.||United States|
|Celexion, LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|NYC2012, Inc.||United States|
|Lawyers Committee for Civil Rights Under Law||United States|
|Rush University||United States|
|Citizens Budget Commission||United States|
Post a JobJobs
- St Louis, MO | Nova BiomedicalPosted: Apr 07
- Gaithersburg, MD | MedimmunePosted: Apr 16
- San Mateo, CA |Posted: Apr 05
- San Francisco, CA | Investment Firm Providing Private and Institutional BrokeragePosted: Apr 07
Sponsored Financial Commentaries
To contact Danube Pharmaceuticals, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.